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Cancer is currently a leading cause of death in the world, with 9.6 million deaths in 2018 alone 
according to the Global Cancer Observatory (GLOBOCAN). Conventional methods such as 
surgery, chemotherapy, and radiotherapy, carry a risk of adverse effects, but without the 
guarantee of remission. To treat B cell acute lymphoblastic leukaemia (B-ALL), single antigen 
directed therapies such as CD19 targeted chimeric antigen receptor (CAR) T cell therapy have 
been developed. Unfortunately, the loss of the CD19 antigen on malignant cells occurs in a 
subset of patients, rendering the tumour cell variants refractory to CAR T cell attack. Targeting 
two antigens in one treatment could counter CD19 antigen loss. We propose using a 
bidirectional promoter to express two CAR constructs on a T cell. A reporter vector using the 
Sleeping Beauty transposon system was developed to determine the bidirectional activity of 
promoters using RFP and GFP. The EF1α, LMP2/TAP1 and synthetic RPBSA promoters, as 
well as RPBSA deletion variants, all showed bidirectional activity in transiently transfected 
HEK293T cells, furthermore bidirectional activity was maintained for over 60 days in stably 
transfected Jurkat cells. Intron deletion from RPBSA led to reduced bidirectional activity, while 
exon deletion resulted in increased activity. Interestingly, at 60 days, the WT RPBSA showed 
the least reduction in bidirectional activity when compared to its deletion variants and was 
therefore selected for further experimentation. Promoters were next compared with other 
constitutive promoters to determine their ability to express a dual CAR. RPBSA effectively 
drove CAR in the sense orientation; however, activity was reduced for CAR expression in the 
antisense direction in HEK293T cells. Introduction of the dual CAR construct into lentiviral 
vectors resulted in low viral titres and compromised transduction into primary human T cells, 
as compared with the single CAR controls. Although the bidirectional promoters could not 
drive CAR expression, they offer the potential for dual expression of shorter mRNA (e.g. 
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There is an estimated 9.6 million deaths attributed to cancer in 2018 alone (GLOBOCAN) (1). 
Conventional treatments of cancers have been challenging, with methods such as surgery, 
chemotherapy and radiotherapy, carrying a risk of adverse effects, but without the guarantee of 
remission (2). Immunotherapy offers an alternative approach to cancer treatment, by 
manipulating the patient’s immune system to target malignant cells. In recent years, 
immunotherapy has emerged as a possible fourth pillar of cancer treatment due to numerous 
successes, such as anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapies against B cell 
acute lymphoblastic leukaemia (B-ALL) and checkpoint inhibitors against anti-apoptotic 
receptors (3). Unfortunately, CAR T cell therapy can select for variants that have mutated the 
targeted antigen, an event known as antigen loss (4). To counter antigen loss, multi-antigen 
specific therapies may be utilised, for example, dual specific CAR strategies to prevent 
dependence on a singular antigen (4,5). However, current dual specific CAR strategies can 
result in low efficacy or are labour intensive and expensive (6). Therefore, the need for novel 
genetic circuits and strategies that reduce cost while retaining efficacy are desperately required. 
 
Immune response to tumours 
The immune response can be divided into two main arms: the innate and the adaptive response. 
Upon infection, the innate immune response activates quickly and non-specifically to pathogen 
associated molecular patterns (PAMPs) through toll-like receptors (TLRs), for example, 
lipopolysaccharides (7,8). This allows phagocytosis and antigen presentation on the major 
histocompatibility complex (MHC) by antigen presenting cells (APCs) such as dendritic cells 
(DCs) and macrophages, as well as inducing inflammation (7,8). The adaptive immune 
response, which involves T and B cells, requires the presentation of peptides using MHC (7,8). 
T cells bearing a T cell receptor specific for the MHC-antigen complex are activated and begin 
to proliferate (7,8). T cells are broadly divided into two types, CD4+ T helper cells that produce 
cytokines essential for directing the immune response, and CD8+ cytotoxic T cells that are 
involved in effector and cytolytic activity against intracellularly infected or tumour cells in an 
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MHC-dependent manner (7,8). In contrast, antibodies are secreted by plasma cells following B 
cell differentiation and are capable of specifically binding to native antigen (7,8).  
While the initial evolution of an immune system focused on the elimination of external 
infectious agents such as microbes, further evolution into higher vertebrate orders resulted in 
greater longevity (9). These ageing populations are associated with greater levels of cancerous 
cell growth (10). The immune system, primarily CD8+ cytotoxic T cells, as well as natural 
killer cells (NK cells), are capable of targeting tumour cells to induce cell death (11). 
Lymphocytes, in particular, T cells present within the tumour are referred to as tumour 
infiltrating lymphocytes (TILs) and are associated with a positive prognosis (11). However, 
despite this, the elimination of tumours remains difficult. This is in part due to the initial 
clearance of highly immunogenic tumour cells, whilst leaving less immunogenic tumour cells 
to survive (12). Simultaneously, tumour cells are capable of generating an immunosuppressive 
environment which reduces the anti-tumour immune response e.g. activation of cytotoxic T-
lymphocyte-associated protein -4 (CTLA-4) or programmed cell death protein 1 (PD-1) 
suppressive pathways involved in T cell apoptosis (12). Overall, the resulting cancer becomes 
efficient at evading the immune system by lowering its immunogenicity and taking advantage 
of inherent suppression pathways (12).  
Tumour immunotherapy involves the manipulation of the patient’s immune cells to eliminate 
tumour cells. Current successful immunotherapies involve CAR T cells that utilise antibody 
binding domains to allow T cells to recognise and target tumour antigen in an MHC-
independent manner (13). Another immunotherapy uses monoclonal antibody checkpoint 
inhibitors to prevent T cells from developing exhaustion characteristics due to chronic antigen 
presentation. These antibodies block inhibitory pathways such as the CTLA-4 and PD-1 
pathways, therefore increasing the proliferation and survival of T cells (2). CD8+ T cells have 
been favoured as the immune cell subset to amplify for cell-based immunotherapies e.g. CAR 
T cell therapy, due to their inherent ability to cause apoptosis and cell death of targeted cells 
(14). Other immunotherapies include cancer vaccines where the patient’s immune cells are 
primed with tumour antigens to generate an anti-tumour response. For example, in 2010 the 
first FDA-approved DC-based cancer vaccine was developed for prostate cancer, utilising an 
autologous patient’s DCs treated with the activation molecule granulocyte-macrophage colony-
stimulating factor (GM-CSF) and prostate tumour antigen PA2024 (11). This allowed the 
development of an immune response directed against the prostate tumour antigen and 
subsequently the prostate tumour. Despite the great potential of immunotherapy, there are still 
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significant challenges to overcome, including the need to achieve a high efficacy while ensuring 
the safety of patients (15). 
 
CARs and previous attempts to improve safety and efficacy 
The CAR consists of the heavy and light chains of an antibody spliced to a transmembrane 
domain and the intracellular signalling domain of the T cell receptor, as well as co-stimulatory 
domains (14,16). The antigen recognition domain or variable domain is expressed as a single 
chain fragment (scFv) (14,16), where the heavy and light chains are bound with a glycine-serine 
linker for flexibility (13). Hence the development of new monoclonal antibodies that target 
overexpressed tumour associated antigens allows for the potential development into a CAR 
construct for immunotherapy. As research into CAR T cell therapy has progressed, different 
generations have been developed to improve their efficacy. The first generation of CARs 
consisted of a simple single chain fragment fused to a transmembrane and CD3ζ domain. The 
CD3ζ is a common domain used to induce the phosphorylation cascade known as the T cell 
activation signal 1 (17). This generation did not work well, largely due to the cell’s inability to 
maintain persistence longer than a few days (17). Therefore, the second generation was 
developed, this added an additional co-stimulatory domain to the construct. Co-stimulation is 
known as signal 2, which is widely regarded as necessary for T cell activation. Co-stimulatory 
domains commonly used are CD28, which favours effector functionality, and 41BB, which 
favours persistence (13,14). The third generation includes both of these co-stimulatory domains 
in a single construct, while the fourth generation also includes cytokine production in the gene 
cassette for additional T cell effector function support (18). 
Currently, the only CAR T cell therapy approved by the FDA for patient treatment is the second 
generation anti-CD19 CAR T cell to treat B-ALL. Two separate therapies, tisagenlecleucel 
(Kymriah) (19) and axicabtagene ciloleucel (Yescarta) (20) were approved by the FDA in 2017 
and 2018, respectively. CD19 is a cell surface protein that functions as a B cell co-receptor, 
aiding in B cell activation by recruiting essential kinases and adaptor molecules (21). In 
addition, CD19 is also found to complex with the co-receptor CD21 on mature B cells. CD19 
is found exclusively on B cells, including B-ALL cells as well as non-malignant B cells (21), 
hence anti-CD19 treatment can result in a loss of normal B cell function, a condition known as 
B cell aplasia. However, B cell aplasia can be successfully treated with antibody replacement 
therapy to fight off any potential infections until the B cell population recovers (22). Also 
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showing potential as an immunotherapy is anti-CD20 CAR T cell therapy that is currently in 
clinical trials (23). CD20 is an antigen on the cell surface of early B cells and is subsequently 
lost when the B cell differentiates into plasma cells (24); however, it is often combined in 
bispecific CAR T cell studies with CD19 as an additional target (5). Other targets in 
development for CAR T cells against B-ALL include CD22 (25), CD30 (26), CD38 (27), CD70 
(28) and CD123 (29), both as single CAR therapies and in conjunction with CD19 (5). 
 
Figure 1 The evolution of CAR constructs. The first generation consisted of the heavy and light chain 
of a monoclonal antibody in a single chain form fused to the transmembrane domain of CD8 and 
intracellular signalling domain of CD3ζ. The second and third generation improved on this design with 
the addition of either co-stimulatory domains CD28 or 4-1BB, or both, respectively. The fourth 
generation, known as T cell Redirected Universal Cytokine killing (TRUCK) involved cytokine 
expression to improve cytotoxicity. Figure adapted from Zhao et al. 2019 (30). 
 
Antigen loss as a strategy for cancer survival in the presence of CAR T cell therapy 
Antigen specific immunotherapy, for example, CAR T cell therapy, can lead to the selection of 
cells expressing mutated antigens, a process known as antigen loss (4,5). This mutation can 
either result in the complete loss of expression on the cell surface or a mutation of the epitope, 
so it is no longer recognisable by the immunotherapy. This renders the immunotherapy 
ineffective and allows the cancer to evade the immune system. An established strategy to 
counter antigen loss is the targeting of multiple antigens in a single therapy, in particular, the 
targeting of two or more antigens allows for the compensation of antigen loss (5).  
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Treatment of antigen loss through multi-antigen targeting can be achieved through four 
different approaches. These are co-administration, co-transduction, bicistronic and tandem 
(Figure 2) (5). Co-administration involves two separate CAR T cell therapies administered in 
the same patient, each targeting a different antigen (Figure 2A) (31). Co-transduction involves 
performing two transfection or transduction events using one T cell population. This creates 
three distinct phenotypes, cells that express either the first or second CAR only, or both CARs 
(Figure 2C).  
These first two approaches were explored by Hegde et al. in 2013 to determine whether the 
targeting of both human epidermal growth factor receptor 2 (HER-2) antigen and interleukin-
13 receptor subunit alpha-2 (IL-13Ra2) on glioblastoma was effective in offsetting the HER-2 
antigen loss normally observed post-HER-2 CAR T cell treatment (31). Hegde et al. found that 
bispecific CAR T cells were both effective at depleting tumour cells as well as producing higher 
amounts of the cytokines interleukin-2 (IL-2) and interferon-γ (IFN-γ) compared to their 
unispecific counterparts (31). While effective in preventing antigen loss by successfully 
targeting two separate antigens, these first two approaches are labour intensive, requiring 
multiple transduction events which can increase the treatment price.  
To combat these issues, strategies for multiple CAR antigen recognition domains in one 
transduction event have been developed. A bicistronic scenario involves two CAR constructs 
in one cassette to generate a phenotype with two CARs expressed on one cell (Figure 2B). This 
was achieved with the strong constitutive promoter eukaryotic translation elongation factor 1 
alpha (EF1α) transcribing two CARs separated by a P2A site by Ruella et al. in 2016 (32). P2A 
sites are small 19-22 amino acid long peptides that contain an ability to self-cleave, known as 
ribosomal skipping. This self-cleavage has led to genetic circuits that translate two proteins 
from a single messenger ribonucleic acid (mRNA). However, the disadvantage of P2A sites is 
that the peptide tag is not removed and therefore amino acids of the P2A site are added to the 
C-terminus of the first gene and the N-terminus of the second gene (33). Hence there is the 
potential for protein misfolding and loss of gene function. Despite this, Ruella et al. found that 
expression of two functioning CAR constructs was possible and that this bicistronic approach 
did indeed prevent antigen loss (32).  
In contrast, tandem constructs use multiple antigen recognition domains with shared 
intracellular signalling domains (Figure 2C). Currently, multiple tandem CAR T cell constructs 
are in clinical trials based around the CD19.20 and CD19.22 tandem CAR constructs (34). 
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These have shown promising results, with three of six patients showing either complete or 
partial response and two of seven patients showing complete response, respectively 




Figure 2 Targeting of multiple antigens as a strategy to combat antigen loss in cancerous tissue. Four 
approaches can be generated when targeting multiple antigens. A) Co-administration involves two 
populations of CAR T cells in a patient. B) Bicistronic involves the expression of two CARs in a 
population of T cells from a singular transduction event. C) Co-transduction involves the generation of 
a bicistronic phenotype in a population by two transduction events. D) Tandem involves two scFv fused 





Promoters used previously/Bidirectional promoters in eukaryotes 
Bidirectional promoters are promoters that allow transcription from both the sense and anti-
sense direction (36,37). In the human genome, 10% of promoters are classed as bidirectional, 
where the genes are arranged in a head-to-head formation with an intergenic region in between 
them that acts as a divergent promoter (37–39). Evidence suggests that human promoters are 
evolutionarily favoured for intrinsic bidirectionality (40). While divergent promoters are 
usually used to describe the divergent transcription of two genes, they are also a major source 
of genetic regulatory elements such as non-coding RNA (ncRNA) (41). Bidirectional promoters 
that transcribe ncRNA would not necessarily require the head-to-head configuration, possibly 
leading to the re-classing of previously identified unidirectional promoters to bidirectional 
promoters (41). 
While there is no guideline to determine whether a promoter is bidirectional, structural core 
elements do exist amongst bidirectional promoters. These include elements such as the TATA 
box, CCAAT box, B recognition element (BRE), initiator element (INR) and downstream 
promoter element (DPE). The TATA box is a very common element that exists in both 
unidirectional and bidirectional promoters. The TATA box allows the binding of transcription 
factor II D (TFIID), a common transcription factor required for the function of RNA polymerase 
II (42). Promoters that lack a recognisable TATA box instead require a CCAAT box, which 
binds the transcription factor NF-Y (43). Nuclear transcription factor Y (NF-Y) subsequently 
allows the binding of TATA binding proteins (TBPs) such as TFIID (43). DPE is an element 
commonly found in TATA-less promoters and serves a similar function as the TATA box, 
allowing the binding of TFIID. While INR is another promoter element that shares a functional 
similarity with the TATA box, allowing the increase in promoter strength in both promoters 
containing either the TATA box or DPE element (36). The BRE consensus sequence allows 
TFIIB to bind, aiding in the initiation of transcription (36). Along with other general 
transcription factors TFIIA, TFIIE, TFIIF and TFIIH, TFIIB and TFIID form the pre-inititiation 
complex with RNA polymerase II (44). RNA polymerase II then enters promoter escape upon 
DNA melting and the addition of nucleotides, forming an open complex (45). As RNA 
polymerase II moves further away from the promoter region, the transcript becomes further 
elongated (45). RNA polymerase II is then released from the DNA upon complete mRNA 
synthesis and available to reinitiate transcription (45). Bidirectional promoters tend to have a 
higher ratio of CCAAT boxes and the BRE element than unidirectional promoters, while the 
ratio of DPE and INR remains largely unchanged (36).  
 
9
Common transcription factors associated with bidirectional promoters are GA-binding protein 
alpha chain (GABP-α), selenocysteine transfer RNA (tRNA) gene transcription-activating 
factor/ zinc finger protein 143 (STAF/ZNF143), Ying Yang 1 (YY1), nuclear respiratory factor 
1 (NRF1), NF-Y and specificity protein 1 (SP1) (36). Several studies have shown the essential 
nature of transcription factors GABP-α and STAF/ZNF143 in divergent transcription. GABP 
and STAF/ZNF143 have shown transcription activation activity. Furthermore, the addition of 
GABP and STAF/ZNF143 binding sites to unidirectional promoters lead to significant 
transcription in the opposite direction (37,39). YY1 is a multifunctional transcription factor, 
involved in transcription initiation. As opposed to other transcription factors, YY1 can act as a 
transcriptional activator in the presence of E1A, while acting as a transcriptional repressor in 
E1A’s absence (46). NRF1 is a transcription factor that serves as a transcriptional activator (47) 
and interacts with SP1 in a protein-protein dependent manner to enhance transcription 
(43,48,49).  
Bidirectional promoters have the potential to streamline constructs in many different fields. The 
utility of bidirectional promoters reduces the size of synthetic constructs. In turn, this leads to 
increased and optimised genetic transfer efficiency, regardless of the transfection method 
(50,51). As an unfortunate drawback to viral transduction is the size restriction of synthetic 
constructs (52), we hope to use bidirectional promoters to minimise the size of our cassette 
while maintaining transduction efficiency. 
 
Lentiviral transduction system 
The lentiviral transduction system allows the introduction of transgenes into the target cell’s 
genome via the heavily altered human immunodeficiency virus (HIV) as the delivery vehicle 
(53). This occurs by taking advantage of HIV’s ability to integrate its positive sense RNA 
genome into the host’s genome via reverse transcriptase and integrase. Through integration, 
Lentiviral transduction can generate stable cell lines across a broad variety of cell types both in 
vitro and in vivo (53). While this is a widely used system, justified concerns of safety surround 
the generation of replication capable viruses that could spread to unintended cells (54). 
There are currently three generations of lentiviral vectors; however, generation one is no longer 
utilised due to safety concerns (53,54). The second generation has removed the accessory genes 
Vif, Vpu, Vpr and Nef, which are essential for replication and not required for one-time 
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transduction events (53,54). The remaining genes are split between three plasmids to prevent 
recombination and the production of replication capable HIV virions (53,54). The first plasmid 
contains the Gag gene, which codes for structural and capsid proteins, the pol gene, which codes 
for genetic integration proteins such as integrase and reverse transcriptase, and the regulatory 
genes Tat and Rev (53,54). The second plasmid contains the VSV-G gene, which replaced the 
original Env gene in the HIV genome to increase the range of cells that lentiviral vectors can 
transduce (53,54). The third plasmid contains the PSI/genome packaging signal followed by 
the transgene under control of the cytomegalovirus (CMV) promoter. This is then flanked by 
long terminal repeats (LTRs) which allow integration into the host genome by integrase (53,54). 
Finally, the third generation involves alterations to the LTR regions on the third plasmid, where 
the U3 region of the 3’LTR is removed to further prevent replication. The U3 region at the 
5’LTR is replaced by a CMV promoter to remove the need for TAT regulation (53,54). This is 
due to their inherent enhancer and activating elements, which could activate potential adjacent 
oncogenes in the host genome. As a result of this, TAT is removed from the first plasmid and 
REV is placed onto a separate plasmid, under the control of CMV (54,55). 
Essential clinical applications of lentiviral vectors involve the restoration of 
immunodeficiencies and the introduction of a T cell receptor or CAR that targets a tumour 
antigen. In terms of immunodeficiencies, lentiviral vectors introduce a healthy wildtype form 
of the gene to rescue function. Therapies to treat diseases such as severe combined 
immunodeficiency (SCID) and sickle cell disease are currently in phase one or further (55). 
One of twenty patients have responded positively to the introduction of a T cell receptor specific 
for cancer antigens NY-ESO-1 and LAGE-1 to treat multiple myeloma. As has been mentioned 
previously, CD19 CAR therapy has been a highly successful FDA approved treatment (55). 
 
Sleeping Beauty (SB) transposon system 
The SB transposon system was developed as a strategy for introducing transgenes into the 
mammalian genome by Ivics et al. in 1997, before additional improvement by Kowarz et al. in 
2015 (56,57). A synthetic cassette is introduced into the genome when the transposase binds to 
the Inverted Tandem Repeats (ITRs) that flank the transgene cassette (Figure 3) (58). The 
transposase enzyme then inserts the cassette into AT rich regions of the genome, allowing for 
successful generation of stable transgenic cell lines (Figure 3). Fluorescent protein and drug 
resistance genes are often included, to track and select for successfully transfected cells post-
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transfection. Two SB systems were developed by Kowarz et al. for commercial application, an 
inducible system, and a bidirectional, constitutive system (57). The inducible system is 
composed of the gene of interest under the control of the tetracycline inducible translational 
control element (TCE) promoter (57). The TCE promoter consists of the tetracycline responsive 
element fused to a modified minimal CMV promoter, while fluorescence, the reverse 
tetracycline transactivator (rtTA) and drug resistance are separated by P2A sites and are under 
the control of the constitutive promoter RPBSA. As a tet-on system, the presence of tetracycline 
allows the rtTA protein to bind the TCE promoter, leading to expression of the gene of interest 
(57).  
RPBSA is a 609 bp constitutive synthetic promoter designed for the Sleeping Beauty transposon 
system (57). RPBSA is composed of the constitutive Ribosomal Protein L13a (RPL13a) 
promoter fused to intron 1 and exon 1, and partial exon 2 of the Ribosomal Protein L41 (RPL41) 
gene. The RPL13a promoter was chosen as the basis for RPBSA due to its strong constitutive 
expression in humans, while the intron for RPL41 gene was included to increase the stability 
of the resulting transcript (57). An advantage of RPBSA is the lack of enhancers required for 
function (57), maintaining a compact size opposed to other common constitutive promoters 
such as CMV and EF1α (59) . The bidirectional system uses both RPBSA and another common 
constitutive promoter, EF1α (57). These promoters are placed in a head to head orientation, 
transcribing in opposite directions. As in the inducible system, fluorescence and drug resistance 
are both under RPBSA, separated by a P2A site, while constitutive expression of the gene of 
interest is under the control of the EF1α promoter (57).  
The possible recombination and replication of viral vectors, although severely hindered, is a 
major safety concern in patients, giving the SB system a strong advantage in the clinical scene. 
SB has primarily been involved in gene therapies in preclinical settings ranging from 
overexpression of coagulation factors to treat haemophilia in mice (60,61) to tyrosinemia by 
overexpression of fumarylacetoacetate hydrolase (62), an enzyme involved in the catabolism 
of the amino acid phenylalanine. SB has also been used for CAR T cell therapy, targeting CD19 
antigen (63). However, due to the lower transfection rates, transduction by lentivirus is still the 




Figure 3 The Sleeping Beauty (SB) Transposon system. A two plasmid arrangement to deliver 
transgenes. One plasmid contains the gene of interest (GOI) flanked by ITR sequences. The other 
plasmid contains the transposase gene driven by a constitutive promoter. The transposon containing the 
GOI is excised and integrated into AT rich regions of the genome. The figure is from Kebriaei et al. 
2017 (65) 
TAP-1/LMP-2 Promoter 
The transporter associated with antigen processing 1 (TAP-1) Low Molecular mass Polypeptide 
2 (LMP-2) promoter is the intergenic region between the genes TAP-1 and LMP-2 (66). These 
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two genes are located on chromosome 6 and organised in a head to head position. This promoter 
region contains an interferon response sequence element (IRSE) that allows the upregulation 
of these two genes (66,67). As both LMP-2 and TAP-1 are essential for the MHC-I antigen 
presentation pathway, they have co-evolved to share an intergenic region that serves as a 
promoter for both genes (66,67). LMP-2 is a beta subunit of the 20S proteasome that is 
upregulated upon viral infection (68,69). Under normal conditions, the 20S proteasome 
degrades proteins tagged for destruction by ubiquitin molecules via beta subunit rings (69). 
Upon viral infection, IFN- γ induces the upregulation of LMP-2, allowing the substitution of 
present beta subunits (69). This is due to its preference for peptide cleavage after hydrophobic 
residues, a prerequisite for MHC-I loading. These shortened peptides are then transported into 
the lumen of the endoplasmic reticulum (ER) via the TAP transporter, which exists as a 
heterodimer of TAP-1 and TAP-2 proteins (69). These peptides are then loaded onto MHC-I 
and expressed on the cell surface for antigen presentation, indicating to the immune system that 
the cell is infected (69).  
 
Project outline 
My project aims to develop a bicistronic phenotype using two CARs to combat antigen loss. 
While a bicistronic phenotype of two CARs has been achieved previously, this has been 
achieved with either two promoters or with P2A sites. This has its disadvantages, primarily a 
larger size and additional modifications, respectively. To reduce the size of the vector as well 
as maintaining minimal modification, we propose generating this bicistronic phenotype through 
the use of a bidirectional promoter. 
Aims 
- To determine the bidirectional activity of RPBSA, EF1α and LMP2/TAP1 using red 
fluorescent protein (RFP) and green fluorescent protein (GFP) as reporter genes. 
- To determine whether the bidirectional promoters can maintain long term bidirectional 
expression. 
- To determine whether the bidirectional promoters can express two CARs  






We hypothesise that RPBSA, EF1α and LMP2/TAP1 promoters will demonstrate bidirectional 
activity and display maintenance of long-term bidirectional expression. We hypothesise that 
the bidirectional promoters will be capable of expressing two CAR constructs simultaneously 




Chapter Two  




2.0 Methods and Materials 
 
2.1 Media and buffers 
 
2.1.1 Lysogeny-Broth (LB)  
 5 g of BactoTM Tryptone, Enzymatic digest of casein (BD #211705) 
 2.5 g of BactoTM Yeast extract (BD #212750)  
 2.5 g of NaCl 
 Volume made to 500 mL with Milli-Q water 
 Autoclaved before use 
2.1.2 LB agar plates 
 500 mL of LB broth 
 7.5 g of agar 
 Autoclaved before use 
 Approximately 25 mL used per plate 
2.1.3 Roswell Park Memorial Institute (RPMI) 1640 
 1 sachet of RPMI 1640 (Gibco #31800-022)  
 100 U/mL penicillin (Gibco #15140-122) 
 100 μg/mL streptomycin (Gibco #15140-122) 
 55 μM β-mercaptoethanol (Gibco #21985-023) 
 2 g of NaHCO3  
 Volume made to 1 L with Milli-Q water 
 pH 7.3 
 0.22 μm filter sterilised 
2.1.4 R5  
 95% RPMI 1640 
 5% foetal calf serum (FCS; Pan Biotech, Germany) 
2.1.5 R10 
 90% RPMI 1640 
 10% FCS  
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2.1.6 Dulbecco's Modified Eagle Medium (DMEM) 
90% DMEM (Gibco #10569-010) 
10% FCS 
100 U/mL penicillin (Gibco #15140-122) 
100 g/mL streptomycin (Gibco #15140-122) 
2.1.7 Dulbecco’s Phosphate Buffered Saline (PBS) 
 1 sachet of PBS (Gibco #21600-010) 
 Volume made to 1 L with Milli-Q water 
 0.22 μm filter sterilised 
2.1.8  2× (NH4)2SO4 buffer 
 150 mM Tris 
 40 mM (NH4)2SO4  
 0.02% (v/v) Tween20 
  Volume made to 1 L with autoclaved Milli-Q water 
2.1.9 Fixation buffer 
1% PFA 
0.1% BSA/PBS 
5 mM EDTA 
Volume made up in PBS 
2.1.10 2× Taq polymerase chain reaction (PCR) master mix 
 2× (NH4)2SO4 buffer 
 4 mM MgCl2 
 0.05 U/µL Taq polymerase (Thermo Scientific #EP0702) 
 0.4 mM dNTPs (Invitrogen #10297018) 
  Volume made up in autoclaved Milli-Q water 




2.1.11 50× TAE buffer 
 272 g of Tris 
 57 mL of glacial acetic acid 
 100 mL of 0.5 M ethylenediaminetetraacetic acid (EDTA) pH 8.0 
 Volume made to 1 L with Milli-Q water 
 pH adjusted to 8.0 with NaOH 
2.1.12 CaCl2 competent E. coli buffer 
 75 mM CaCl2 dihydrate 
 10 mM piperazinediethanesulfonic (PIPES) acid 
 15% glycerol 
 Volume made to 200 mL with autoclaved Milli-Q water 
 pH 7.0 
 0.22 μm filter sterilised 
2.2 Cell lines 
Jurkat 
 Species: Human 
 Type: T lymphocyte 
 Clone: E6.1 
 Source: ATCC 
HEK293T 
 Species: Human 
 Type: Embryonic Kidney 




2.3 Table 1 Restriction enzymes 
 
2.4 Table 2 Primers 
Primer name Primer sequence Restriction 
enzyme 




PAC FWD CTCTAACCTGAGGAGTGAATTCACG Bsu36I 
PAC REV GCGGCCGCAGGCAGTGGAGCTACTAAC NotI 
GFP FWD CTCTACCCGGGCCACCATGTTGAGCAAGGGC XmaI 




temperature and time 
Bsu36I (NEB #R0524S) 37C, 1 h 80C, 20 min 
HindIII-High Fidelity (HF)(NEB #R3104S) 37C, 1 h 80C, 20 min 
NcoI-HF (NEB #R3193S) 37C, 1 h 80C, 20 min 
NheI-HF (NEB #R3131S) 37C, 1 h 80C, 20 min 
NotI-HF (NEB #R3189S) 37C, 1 h 65C, 20 min 
SalI-HF (NEB #R3138S) 37C, 1 h 65C, 20 min 
BamHI-HF (NEB #R3136S) 37C, 1 h N/A 
ClaI (NEB #R0197S) 37C, 1 h 65C, 20 min 
EcoRV-HF (NEB #R3195S) 37C, 1 h 65C, 20 min 
XmaI (NEB #R0180S) 37C, 1 h 65C, 20 min 
rSAP (NEB #M0371S) 37C, 30 min 65C, 5 min 
T4 DNA Ligase (NEB #M0202S) 16C, overnight 65C, 10 min 
T4 polynucleotide kinase (NEB #M0236S) 37C, 1 h 65C, 20 min 
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GFP REV CTCTCAAGCTTTCACTTGTACAGCTCGTCCATGC HindIII 










EF1α REV CTCTACCCGGGGGCTCCGGTGCCCGTC XmaI 










GFP qPCR FWD AGGACGACGGCAACTACAAG  
GFP qPCR REV TTGTACTCCAGCTTGTGCCC  
RFP qPCR FWD GCTTCAAGGTGCGCATGGAG  
RFP qPCR REV TCGAAGTTCATCACGCGCTC  
GFP FWD TTATTGGATCCCCACCATGTTGAGCAAGGGC BamHI 
CD3 REV TTATTGTCGACTTAGCGAGGGGGCAGGGCC SalI 
CD20 CAR FWD TTATTGATATCGCCACCATGCGAAGGATGCAA EcoRV 















2.5 Table 3 Sleeping Beauty plasmids 
Dual fluorescent vectors 
pSB-GFP-RPBSA-RFP 
pSB-GFP- RPBSA ∆Intron -RFP 




2.6 Table 4 Lentivirus vectors 
Dual CAR vectors Single CAR vectors (Controls) 
pCCLsin CAR19-EF1α-GFP-CAR20 pCCLsin EF1α-GFP-CAR19 
pCCLsin CAR19-CMV-GFP-CAR20 pCCLsin CMV-GFP-CAR19 
pCCLsin CAR19-HPGK-GFP-CAR20 pCCLsin hPGK-GFP-CAR19 
pCCLsin CAR19-RPBSA-GFP-CAR20 pCCLsin RPBSA-GFP-CAR19 
pCCLsin CAR19-LMP2/TAP1-GFP-CAR20 pCCLsin EF1 α-GFP-CAR20 
pCCLsin CAR19-LMP2/TAP1(Flipped)-CAR20  
 
2.7 Restriction enzyme digest 
Restriction digests were completed according to the manufacturer’s instructions. In brief,  
20 units of enzyme (See 2.3) with 1 μg of plasmid deoxyribonucleic acid (DNA) or of 
geneblock DNA was mixed in 1× cutsmart buffer (NEB #B72045) diluted in milli-Q water. 
This reaction was then incubated at 37°C for 15 min before the enzymes were heat inactivated 
at 80°C for 20 min. Geneblock digests were then purified by Monarch PCR and DNA cleanup 
kit (see 2.10), while plasmid digests were then dephosphorylated with one unit of shrimp 
alkaline phosphatase (rSAP; NEB #M0371S) per 20 μL and heat inactivated at 65°C for 5 min 
before incubation at 37°C for 30 min. Geneblock digests that were cut with blunt end restriction 
enzymes (EcoRV) were then phosphorylated with one unit of T4 polynucleotide kinase  
(PNK; NEB#M0201S). Digests were then loaded and run by gel electrophoresis (see 2.11). 
 
22
 The appropriate bands were extracted from the resulting agarose gel using a Monarch gel 
extraction kit (see 2.12) 
 
2.8 Q5 Polymerase Chain Reaction (PCR) 
The Q5 PCR mix consists of a final concentration of 50 ng of template DNA, 1× Q5 Reaction 
Buffer (NEB #B9027S) diluted in MilliQ H2O, 200 M dNTP solution mix (NEB #N0447L), 
0.5 M each of the appropriate SB forward and reverse primers, 0.02 U/L Q5 High-Fidelity 
DNA Polymerase (NEB #M0491L), and 1× Q5 High GC Enhancer (NEB #B9028A), for a total 
reaction volume of 50 L. The following PCR protocol was followed: 98C for 30 s;  
25-35 cycles of 98C for 10 s, 60°C for 20 s, 72C for 20-30 s per kb; 72C for 2 min. The PCR 
products were then analysed using gel electrophoresis and a Purple 1Kb+ DNA ladder on a 1% 
agarose gel containing 1× SYBR Safe (see 2.11). Gels were imaged using a Li-Cor Odyssey Fc 
instrument at 600 nm.  
 
2.9 Q5 SOE PCR (Splicing by Overlapping Extension Polymerase Chain Reaction) 
Q5 SOE PCR consists of two stages, initial splicing of the two gene products and resolution of 
the final product. The Q5 SOE PCR mix consists of a final concentration of 100 ng each of the 
appropriate gene products, 1× Q5 Reaction Buffer (NEB #B9027S) diluted in MilliQ H2O,  
200 M dNTP solution mix (NEB #N0447L), 0.02 U/L Q5 High-Fidelity DNA Polymerase 
(NEB #M0491L), and 1× Q5 High GC Enhancer (NEB #B9028A), for a total reaction volume 
of 50 L. The following PCR protocol was followed: 98C for 30 s; 10 cycles of 98C for  
10 s, 50 for 20 s, 72C for 20-30 s per kb; 72C for 2 min. 0.5 M each of the appropriate 
forward and reverse primers were added before the following PCR protocol was performed: 
98C for 30 s; 20 cycles of 98C for 10 s, 60 for 20 s, 72C for 20-30 s per kb; 72C for 2 min. 
The PCR products were then analysed by gel electrophoresis (see 2.11). Gels were imaged 




2.10 Purification of DNA 
The Monarch PCR and DNA cleanup kit (NEB #T1030L) was used to purify DNA fragments 
following the manufacturer’s instructions. In brief, a 5:1 ratio of cleanup binding buffer to 
geneblock was added, loaded onto a spin column with a collection tube and spun at 16,000 ×g 
for 1 min. The spin column was then washed twice with DNA wash buffer, spinning at  
16,000 ×g for 1 min. The column was transferred to a new microcentrifuge tube and eluted 
twice with 6 μL of elution buffer, incubating for 1 min at room temperature and spinning at 
16,000 ×g for 1 min between elutions. The DNA concentration was determined using a 
Nanodrop 1000 at 260 nm. 
 
2.11 Gel electrophoresis 
Agarose gels were prepared using 1% SeaKem LE agarose (Lonza #50000) dissolved in  
50 mL of 1× TAE buffer, and contained 1× SYBR Safe DNA Gel Stain (Invitrogen #S33102). 
DNA was stained with 3 μL of loading dye per lane and band sizes identified by comparison to 
a Purple 1Kb+ DNA ladder (6 µL; NEB #N0550S). The gel was run at 95 V, 300 mA for 1 h 
and imaged using a Li-Cor Odyssey Fc instrument at 600 nm.   
 
2.12 Extraction of DNA from agarose gel 
The Monarch gel extraction kit (NEB #T1020L) was used to extract DNA from agarose gels 
following the manufacturer’s instructions. In brief, the band of interest was excised from the 
agarose gel using a scalpel and weighed. A 4:1 ratio of gel dissolving buffer (µL) per 100 mg 
of agarose gel was added to the band of interest. The sample was incubated at 50°C for 10 min, 
with vortexing periodically until the gel had dissolved. The sample was then loaded into a spin 
column with a collection tube and spun at 16,000 ×g for 1 min. The spin column was washed 
twice with 200 μL of wash buffer by spinning at 16,000 ×g for 1 min. The column was 
transferred to a new microcentrifuge tube, eluted twice by adding 6 μL of elution buffer, 
incubating for 1 min at room temperature and spinning at 16,000 ×g for 1 min between elutions. 




2.13 Ligation of DNA 
For sticky end ligations, the ligation mix consisted of 2 μL of T4 buffer, 400 units of T4 ligase, 
7 μL of restriction enzyme digested vector and 10 μL of restriction enzyme digested insert of 
interest. For blunt end ligations, the ligation mix consisted of 2 μL of T4 buffer, 400 units of 
T4 ligase, 2 μL of restriction enzyme digested vector, 8 μL of restriction enzyme digested insert 
of interest and 4.5 μL of Milli-Q water. The sticky-end ligation mix was then incubated at 20°C 
for 2 h, before heat inactivated at 65°C for 10 min, while the blunt end ligation mix was 
incubated at 16°C overnight. 
 
2.14 CaCl2 competent E. coli 
A 3 mL starter culture of E. coli Top10 was made in LB broth media and incubated at 37°C 
with shaking at 200 rpm overnight. A 1:100 dilution of starter culture to LB broth media was 
made i.e. 2 mL of starter culture was added 200 mL of LB broth media. This was incubated at 
37°C with shaking at 200 rpm until an OD600 of 0.35-0.45 was reached. This larger culture was 
split into four pre-chilled 50 mL Falcon tubes and incubated on ice for 20 min before 
centrifuged at 2000 ×g for 10 min at 4°C. Supernatants were decanted and each pellet 
resuspended in 20 mL of ice-cold CaCl2 competent E. coli buffer and incubated on ice for  
20 min before centrifuged at 2000 ×g for 10 min at 4°C. Supernatants were decanted and each 
pellet resuspended in 2 mL of ice-cold CaCl2 competent E. coli buffer. CaCl2 competent 
bacteria were then aliquoted (50 µL/tube) into pre-chilled microcentrifuge tubes at -80°C before 
stored at -80°C. 
 
2.15 Transformation of bacteria 
A 50 μL aliquot of competent E. coli was thawed on ice before either 100 ng of purified plasmid, 
or half of a plasmid ligation mix was added and incubated on ice for 30 min. The  
E. coli and plasmid mix was then heat shocked at 42°C for 90 s before being placed on ice 
immediately for 5 min. This mix was then added to 1 mL of pre-warmed LB broth media and 
regenerated at 37°C for 1 h before 25-50 μL was plated on LB agar plates with appropriate 




2.16 Colony PCR 
Selected colonies were touched with a sterile pipette tip, where it was used for streaking onto 
an LB agar plate with appropriate antibiotics before transferring to 15 μL of PCR master mix. 
The PCR master mix consisted of a final concentration of 250 nM of the appropriate forward  
and reverse primers and 1× Taq master mix diluted in milli-Q water. The following PCR 
protocol was followed: 95°C for 2 min; 35 cycles of 95°C for 30 s, 54°C for 30 s, 72°C for  
1 min/kb; 72°C for 5 min. The PCR products were then analysed using gel electrophoresis  
(see 2.11). Gels were imaged using a Li-Cor Odyssey Fc instrument at 600 nm.  
 
2.17 Miniprep plasmid purification 
The Monarch plasmid DNA miniprep kit (NEB #T1010L) was used to purify plasmid DNA 
from bacterial cultures as per the manufacturer’s instructions. In brief, a 1 mL of overnight 
culture of the bacteria containing the plasmid of interest was centrifuged at 17,000 ×g for  
5 min, the supernatant decanted and pellet resuspended in 200 μL of resuspension buffer. Cells 
were lysed by the addition of 200 μL of lysis buffer, followed by inversion for gentle mixing 
and incubated at room temperature for 1 min. The reaction was neutralised by the addition of 
400 μL of neutralisation buffer, followed by inversion until the solution formed a uniform 
yellow colour and incubated for 1 min at room temperature. This solution was spun at  
17,000 ×g for 5 min to clarify the lysate before transferring the supernatant to a spin column 
and spinning at 17,000 ×g for 1 min. The spin column was then washed twice with 200 μL of 
wash buffer 1 and 2, respectively, before the addition of 40 μL of elution buffer and incubating 
at room temperature for 2 min. Finally, this spin column was spun at 16,000 ×g to elute the 
plasmid DNA, where the plasmid DNA concentration was quantified with the Nanodrop 1000 
at 260 nm. 
 
2.18 Midiprep plasmid purification 
The NucleoBond® Xtra Midi Plus kit (Macherey-Nagel #740412.50) was used to purify 
plasmid DNA bacterial cultures as per the manufacturer’s instructions. In brief, a 150 mL of 
overnight culture of the bacteria containing the plasmid of interest was centrifuged at  
6,000 ×g for 10 min at 4C then resuspended in 8 mL of ‘Resuspension Buffer RES + RNase 
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A’. Cells were lysed by the addition of 8 mL of lysis buffer followed by inversion for gentle 
mixing and incubated at room temperature for 5 min. The reaction was neutralised by the 
addition of 8 mL of neutralisation buffer, followed by inversion until the solution goes 
colourless. The sample was then immediately loaded onto a column filter that was equilibrated 
with 12 mL of equilibration buffer. The column filter was then washed with  
5 mL of equilibration buffer before the filter was discarded and the column washed with  
8 mL of wash buffer. The plasmid of interest was then eluted off the filter using 5 mL of elution 
buffer into a 15 mL falcon tube. The plasmid DNA was precipitated with the addition of  
3.5 mL of isopropanol and vortexed well before incubation at room temperature for 2 min. This 
solution was then loaded onto a NucleoBond Finalizer and washed with 2 mL of  
70% ethanol. The finalizer was air dried before the plasmid DNA was eluted using 1 mL of 
TRIS buffer. The plasmid DNA concentration was quantified with the Nanodrop 1000 at  
260 nm. 
 
2.19 Jurkat cell culture 
Jurkat cells stored in liquid nitrogen were thawed in R10 (pre-warmed to 37°C) and centrifuged 
at 453 ×g for 5 min. Pellets were resuspended in 10 mL of R5 (pre-warmed to 37°C) and 
transferred to a 75 cm2 cell culture flask before incubation at 37°C with 5% CO2. Jurkat cells 
were maintained at an approximate concentration of 1×105 cells/mL in R5. 
 
2.20 HEK293T cell culture 
HEK293T cells stored in liquid nitrogen were thawed in DMEM (pre-warmed to 37°C) and 
centrifuged at 453 ×g for 5 min. Pellets were resuspended in 10 mL of DMEM (pre-warmed to 
37°C) and transferred to a 75 cm2 cell culture flask before incubation at 37°C with  





2.21 Lipofectamine 3000 transfection  
The Lipofectamine 3000 transfection kit (L3000-015) was used to transfect transgenes into 
HEK293T cells following the manufacturer’s instructions. In brief, HEK293T cells were 
resuspended in DMEM without antibiotics at 4×105 cells/mL and then 500 µL of HEK293T 
cells were then added into a 24 well plate and incubated overnight at 37°C. Following this,  
1.5 µL of Lipofectamine 3000 reagent was diluted in 25 µL of OptiMEM (Invitrogen 
#100022058) in a microfuge tube. At the same time, 100 ng of pCMV(CAT)T7-SB100 
(transposase containing plasmid) and 400 ng of Sleeping Beauty plasmid (See 2.5) was diluted 
in 25 µL of OptiMEM. The diluted Lipofectamine reagent was then added to the diluted DNA 
mixture and incubated at room temperature for 15 min before being added dropwise to the 
HEK293T cells. The cells were then incubated overnight before the lipofectamine was removed 
and replaced with DMEM without antibiotics. 
 
2.22 Neon transfection 
The Neon transfection kit (Invitrogen #MPK10025) was used to transfect transgenes into Jurkat 
cells following the manufacturer’s instructions. In brief, Jurkat cells were washed once in PBS 
and resuspended in “resus buffer R” (Invitrogen #MPK10025) at a concentration of  
2×107 cells/mL. Immediately prior to transfection, 110 µL of Jurkat cells were added to a 
microfuge tube containing 1 µg of pCMV(CAT)T7-SB100, plus 4 µg of the plasmid of interest 
(See 2.5). Using 100 µL neon gold tips, 100 µL of the cell:plasmid mix was then added to the 
electroporation tube holder containing 3 mL of electrolytic buffer. Cells were electroporated 
with three pulses at 1350 V for 10 ms and then added to 4 mL of pre-warmed R10 media 
containing no antibiotics in a 6-well plate. 
 
2.23 Lentiviral production and viral titre calculation 
The following lentiviral procedure was performed by Ali Hosseini Rad (Dept. of Microbiology 
& Immunology, University of Otago, Dunedin, NZ). For each lentivirus preparation,  
22.1 × 106 of HEK293T (ATCC® CRL-3216) were plated in a T150 tissue flask in 10% 
FCS/DMEM, Glutamax (Gibco). On the next day, cells were transfected with 13.8 µg of 
transfer plasmid (pCCLsin) and 41.4 µg packing plasmids (pRRE, pRSV, VSVG) with 
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Lipofectamine 3000 reagent (Thermofisher), according to manufacturer’s protocol. The 
medium was changed daily with 5% FCS/Optimem with 100 U/mL Penicillin/Streptomycin 
(Gibco) at 24 and 48 h post-transfection. Both time point transfections were pooled and 
centrifuged at 120,000 × g for 2.5 h at 4°C. Finally, lentivirus was resuspended in CTS 
optimizer T Cell Expansion media (Thermofisher) and stored at -80°C.  
All vectors were titrated on HEK293T cells using eGFP as detection. On the day of 
transduction, virus dilutions were prepared with fresh medium supplemented with 1 mg/mL 
polybrene (Sigma-aldritch #TR-1003) and a titration of each virus started from 10-2 to 10-5. 
HEK293T cells with virus were spinoculated at 800 × g for 30 min. Three days later, GFP-
positive cells of each construct were analysed by flow cytometry. Titer was calculated via 
formula = Frequency of GFP-positive cells × number of cells/volume of virus × lentivirus 
dilution factor. 
. 
2.24 HEK293T cell transduction 
Transduction of HEK293T uses the same method as viral titre calculation described above and 
was performed by Ali Hosseini Rad (Dept. of Microbiology & Immunology, University of 
Otago, Dunedin, NZ). In brief, 5 × 105 HEK293T cells were seeded on a 24 well plate. The 
same amount of TU was normalised amongst each construct (See 2.6) before transduction. On 
the day of transduction, concentrated virus of MOI 20 was prepared with fresh medium 
supplemented with 1 mg/mL polybrene. HEK293T cells with virus were then spinoculated at 
800 × g for 30 min. Analysis by flow cytometry checking for GFP and c-Myc/Strep tag was 
performed after three days (See 2.28 and 2.29) 
 
2.25 Human CD8 T Cell transduction 
The following lentiviral procedure was performed by Ali Hosseini Rad (Dept. of Microbiology 
& Immunology, University of Otago, Dunedin, NZ). Human peripheral blood mononuclear 
cells (PBMC) were sourced from healthy adult donors; their use and manipulation within this 
study were approved by the University of Otago Human Ethics Committee. PBMC were first 
isolated by Ficoll Hypaque, after which human T cells were isolated with Easy Sep Human T 
cell isolation kit (Easy Sep) according to the manufacturer’s protocol. 1.0 × 106 cells/mL of T 
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cells were plated at 48 well in T cell expansion media supplemented with 50 U/mL human IL-
2 (Peprotech). T cells were activated with activator CD3/CD28 dynabeads (Gibco #11132D) at 
a ratio of one bead per cell. Lentiviral transduction was conducted at 48 h post-activation. A 
24-well plate was coated with 40 µg/mL retronectin (Takara # T100B) overnight at 4°C, 
followed by blocking with 2% BSA/PBS for 30 min at room temperature and finally washed 
with PBS. A concentrated virus of MOI 20-40 was plated in the retronectin coated 24-well plate 
and centrifuged for 2 h at 2000 ×g at 25 °C. The virus was then removed from the plate and  
0.5 × 105 activated T cells were added into each well before centrifugation for 30 min at  
453 ×g for 25 °C. The beads were then removed from the cells the following day according to 
the manufacturer’s protocol. Medium supplemented with human IL-2 (50 U/mL) was renewed 
every three days, and the cell density maintained at 1 × 106 cells/mL. 
 
2.26 Puromycin selection 
Puromycin was used to select for Jurkat cells successfully transfected with the chosen plasmids. 
At 24 h post-transfection 2 µg/mL puromycin was added to the cells and maintained for  
2-3 weeks to ensure that selection for transfected cells was successful and only transfected cells 
remained. Post 2-3 weeks transfection, the concentration of puromycin was reduced to 1 µg/mL 
to ensure continued expression of transfected transgenes. 
 
2.27 Fluorescent microscopy 
Cells were viewed using an Olympus IX-71 inverted microscope. For HEK293T cells, 
Brightfield, GFP and RFP pictures were exposed and taken with an exposure time of 
approximately 43 ms, 1.7 s and 300 ms, respectively, at 20× magnification. For Jurkat cells, at 
day 30, Brightfield, GFP and RFP pictures were taken at an exposure time of approximately 17 
ms, 4 s and 1 s, respectively, at 4× magnification. At day 60, Brightfield, GFP and RFP pictures 





2.28 Flow cytometric staining 
Cells (200,000 per tube) were washed by resuspending in 1 mL of 0.1% BSA/PBS/2 mM 
EDTA, followed by centrifugation at 453 ×g for five min at 4°C. Pelleted cells were 
resuspended in 50 µL of 2 µg/mL biotinylated anti-c-myc mAb (Biolegend #908805) or  
2 µg/mL anti- Strep Tag IgG (BioLegend #688202; clone BL26882), and incubated for 30 min 
on ice in the dark. Cells were washed as described above. The anti-c-myc antibody was detected 
by resuspending cells in 50 µL of 1 µg/mL allophycocyanin-conjugated streptavidin (Biolegend 
#405207), while the anti-strep tag antibody was detected by resuspending cells in 50 µL of  
1 µg/mL donkey anti-mouse IgG Alexa Fluor 680 (ThermoFisher #A10038). Cells were then 
incubated for 30 min on ice in the dark and washed as described above. Stained cells were then 
resuspended in 400 µL of 0.1% BSA/PBS/2 mM EDTA and stored in the dark on ice before 
flow cytometric analysis. 
2.29 Flow cytometry 
Presence and intensity of fluorescence (RFP/GFP) was measured using the BD LSRFortessa 
with BD FACSDiva software and quantified using FlowJo software. HEK293T cells were 
washed in PBS and resuspended in FACS fix buffer. Jurkat cells were washed once in PBS and 
resuspended in PBS prior to acquisition. Populations were gated on live cells using SSc and 
FSc (Area) before gating on green (B_530_30-A) and red fluorescence (YG_586_15-A). 
Alternatively, anti-c-Myc and anti-Strep Tag stained cells were gated on allophyocyanin 
(R_670_14-A) and Alexa Fluor 680 (R_730_45-A). 
2.30 RNA extraction 
The nucleospin® RNA plus kit was used to extract RNA from HEK293T cells according to the 
manufacturer’s instructions. In brief, 1×106 cells were lysed by the addition of 350 µL of ‘LBP’ 
buffer. The sample was then transferred to a Nucleospin® gDNA removal column (Yellow 
ring) and spun at 11,000 ×g for 30 s. Next 100 µL of ‘Binding Solution BS’ was added to the 
flow through and mixed thoroughly by pipette. The whole lysate was then transferred to the 
Nucleospin® RNA plus column (light blue ring) and spun at 11,000 ×g for 15 s. The spin 
column was then washed with 200 µL ‘WB1’ buffer and 600 µL ‘WB2’ buffer before a final 
wash of 250 µL ‘WB2’ buffer. Finally, this spin column was spun twice at 11,000 ×g for 1 min 




2.31 cDNA generation from RNA 
RNA was converted to cDNA using the Takara kit according to the manufacturer’s instructions. 
In brief, the mix consisted of a final concentration of 1× buffer, 0.5 µL of Oligo dT, 2 µL of 
random hexamer, 0.5 µL of enzyme and 5 µL of reverse transcriptase. This mix was incubated 
as follows: 25°C for 15 min; 37°C for 15 min, 42°C for 15 min, 80°C for 5 min. The cDNA 
was then used for qPCR (see 2.32).  
 
2.32 qPCR 
cDNA was diluted 1 in 2 using RNAse free water before qPCR reaction. qPCR amplifications 
were performed in 10 µL reactions containing 1 µL cDNA, 5 µL of 2 × qPCR MasterMix Plus 
SYBR® green I (Thermo Scientific #4309155) reaction buffer (with HotStar Taq polymerase), 
3 µL of Milli-Q water and 1 µM of forward and reverse primers. For each target region or 
primer, reactions were performed in duplicate with the test RNA samples, and separate 
duplicate reactions were performed using a reference gene β-actin. Test primers and control 
primer for each RNA sample was run on the same plate. 
 
2.33 DNA sequencing 
DNA was amplified using 3.2 pmol/5 μL of the appropriate plasmid forward and reverse 
primers, before it was sequenced using an ABI 3730xl DNA analyser at the Genetic Analysis 
Services by the Department of Anatomy, University of Otago, Dunedin, NZ. 
 
2.34 Data analysis and presentation 
Images of agarose gels containing SYBR Safe stained DNA were analysed in Image Studio 
Lite 5.2.5 software. DNA sequences were analysed with Geneious 11.1.5 software. Data was 
graphed with Graphpad prism 7.05 or Microsoft Excel 2016. Flow cytometry data was analysed 
with Flowjo software version 10.2. 






3.1 Selection of promoters to test 
Initially, promoters were screened for transcription factors associated with bidirectional 
promoters according to Orekhova et al (36), predicted using the Promo alggen database  
(Figure 4). RPBSA was chosen due to the over representation of these transcription factors after 
bioinformatic analysis. Previous work using RPBSA also showed bidirectional transcription 
through a smaller promoter organised in a back-to-back formation in previous work in the 
McLellan laboratory. This smaller promoter was inducible and therefore expression of the gene 
under the smaller promoter’s control should not have been expressed. As the majority of 
transcription binding sites are clustered in the RPL13 promoter section, we sought to determine 
whether deletion of the intron and exons would affect the strength of bidirectional activity. In 
particular, we investigated the effect of deleting either the intron, or the intron and exons of 
RPBSA (Figure 4).  
LMP2/TAP1 promoter was also selected for bidirectional analysis. This promoter has already 
been shown to be bidirectional, with the presence of the ISRE allowing for upregulation in the 
presence of IFN-γ and tumour necrosis factor-α (TNF-α) (66). For example, the LMP2/TAP1 
promoter would provide autoregulation of CAR constructs, where antigen interaction with 
surface expressed CAR on T cells leads to the release of IFN-γ and TNF-α, which in turn results 
in upregulation of CAR surface expression. 
Finally, the EF1α promoter was also chosen for bidirectional analysis. As a strong constitutive 
promoter (70), EF1α also exhibits moderate bidirectional activity (71). Genetic circuits that 
require the constant expression of CARs alongside either another CAR construct or regulatory 
































































































































3.2 Cloning of Sleeping Beauty constructs 
To determine the bidirectional activity of the chosen promoters, a modular vector was designed 
to allow for the simple replacement of promoters and genes. This modular vector utilises the 
Sleeping Beauty transposon system to deliver the transgenes (Figure 5). Initially, to validate 
bidirectional activity in the chosen promoters, restriction enzymes were used to clone the GFP 
gene in the reverse orientation (HindIII and NheI) or the RFP gene in the forward orientation 
(NcoI and NotI), or the promoter to be studied (NheI and NcoI) (Figure 5). The puromycin-
resistance gene was fused to the forward direction gene of interest separated by a P2A site. 
Expression of both fluorescent proteins using these dual fluorescent constructs would allow us 






Figure 5 Cloning strategy to determine bidirectional activity in promoters using the Sleeping 
Beauty transposon system. A) A Schematic illustration of the Sleeping Beauty backbone bearing 
five promoters (EF1α, LMP2/TAP1, RPBSA WT, RPBSA ΔIntron, RPBSA ΔIntron/Exon) for driving 
RFP-P2A-Puromycin in the sense direction and GFP in the antisense direction. B) A plasmid map 




3.3 Fluorescent protein expression in HEK293T cells 
Dual fluorescent constructs containing multiple promoters to be trialled (Figure 5) were 
transiently transfected into HEK293T using a cationic lipid-based transfection reagent 
(Lipofectamine 3000). HEK293T and Lipofectamine 3000 were used for initial testing as 
results can be achieved quickly while maintaining a high transfection rate. This transfection 
rate also allows for the removal of the drug selection step by puromycin. Transfected HEK293T 
were left to grow for one week before analysis by bright field and fluorescent microscopy in 6 
well plates (Figure 6), quantitative PCR (qPCR) (Figure 7) and flow cytometry (Figure 8). 
Fluorescent microscopy and flow cytometry quantify the strength of the respective promoters 
at a protein level, whereas qPCR determines the strength of the promoters at an mRNA level. 
As shown in Figures 6-8, the wild type (WT) RPBSA promoter expresses activity in both the 
sense and antisense directions. However, upon deletion of the intron, expression levels of both 
RFP and GFP were reduced. Interestingly, upon further deletion of exons 1 and 2, expression 
of GFP and RFP return to that observed for full length RPBSA levels or higher. EF1α and 
LMP2/TAP1 promoters were also tested for bidirectional activity, confirming bidirectional 






Figure 6 Analysis of transfected HEK293T cells by light fluorescent microscopy one week after 
transfection. HEK293T cells were transfected in duplicate with the indicated promoter constructs 
and analysed. Brightfield, GFP and RFP pictures were exposed and taken with an exposure time of 
approximately 43 ms, 1.7 s and 300 ms, respectively, at 20× magnification. Scale bar: 200 μm. 







Figure 7 Analysis of transfected HEK293T cells by qPCR one week after transfection. A) β-actin, 
GFP and RFP primers and their respective threshold cycles in an untransfected HEK293T.  
B) Examples of β-actin, GFP and RFP primers and their respective threshold cycles in transfected 
HEK293T C) Melt curve plot of β-actin, GFP and RFP primers. D) Quantitative PCR (qPCR) to 
measure expression of GFP and RFP at mRNA level one week after transfection normalised against 






Figure 8 Analysis of transfected HEK293T cells by flow cytometry one week after transfection. 
HEK293T cells were transfected with the indicated promoter construct and analysed by flow 
cytometry after one week. A) and B) Percent positive and Median Fluorescent index (MFI) statistics 
of HEK293T cells analysed by flow cytometry, respectively. C) Flow plots of HEK293T cells gated 




3.4 Time course of fluorescent protein expression in Jurkat cells 
Dual fluorescent constructs containing the promoters to be investigated (Figure 5) were 
transfected into the T cell line Jurkat using the electroporation Neon transfection system. Jurkat 
cells were used as they are an accurate model for human primary T cells activity (72). To 
determine if the expression of proteins by the promoters could be maintained for long lengths 
of time, these cell lines were then maintained for 60 days, with analysis by bright field and 
fluorescent microscopy, as well as flow cytometry at days 30 and 60 (Figures 9-12). This 
analysis was performed once. A similar trend to the HEK293T cells was observed where a 
reduction in bidirectional expression from WT RPBSA to RPBSA ∆Intron 1 was observed. 
Restoration of function with the further deletion of exons 1 + 2 can also be seen in Jurkat cells 
EF1α and LMP2/TAP1 promoters remain bidirectional and transcriptionally active. 
Interestingly, between day 30 and day 60, bidirectional activity in all promoters was reduced, 
with a small proportion of the population silencing their fluorescent expression. Between 
RPBSA and its deletion variants, WT RPBSA had the lowest reduction in MFI and percent 
positive cells while maintaining high expression numbers and was therefore used for further 
experiments. As the LMP2/TAP1 promoter also maintained bidirectional activity with minimal 






Figure 9 Analysis of transfected Jurkat cells by light fluorescent microscopy 30 days after 
transfection. Light microscopy to visualise transfected Jurkat cell 30 days after transfection. 
Brightfield, GFP and RFP pictures were taken at an exposure time of approximately 17 ms, 4 s and 






Figure 10 Analysis of transfected Jurkat cells by flow cytometry 30 days after transfection. 
Jurkat cells were transfected with the indicated promoter construct and analysed by flow 
cytometry after 30 days. A) and B) Percent positive and Median Fluorescent index (MFI) statistics 
of Jurkat cells analysed by flow cytometry, respectively. C) Flow plots of Jurkat cells gated on 





Figure 11 Analysis of transfected Jurkat cells by light fluorescent microscopy 60 days after 
transfection. Light microscopy to visualise transfected Jurkat cell 60 days after transfection. 
Brightfield, GFP and RFP pictures were taken at an exposure time of approximately 17 ms, 4 s and 





Figure 12 Analysis of transfected Jurkat cells by flow cytometry 60 days after transfection. Jurkat 
cells were transfected with the indicated promoter construct and analysed by flow cytometry after 
60 days. A) and B) Percent positive and Median Fluorescent index (MFI) statistics of Jurkat cells 
analysed by flow cytometry, respectively. C) Flow plots of Jurkat cells gated on cells positive for 







Table 5 Fluorescent protein analysis in the HEK293T and Jurkat cell lines. Numbers from 
figures and compiled into a table. ^ = HEK293T cell line work was done in duplicate, the mean 
values are displayed. * = qPCR values are measured in fold change normalised against the 
housekeeping gene β-actin. UN = Untransfected 
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3.5 Cloning of lentiviral constructs 
To determine if the bidirectional activity of the chosen promoters were strong enough to express 
two CAR constructs, a modular vector was designed to allow for simple replacement of 
promoters and genes. This modular vector utilises the pCCLsin plasmid to carry the transgenes 
(Figure 13), which is then packaged into a lentiviral virion using the packaging plasmids 
VSVG, pRSV and pRRE. The restriction enzymes ClaI and EcoRV were used to clone the anti-
CD20 CAR in the reverse orientation, while BamHI and SalI were used to clone GFP and the 
anti-CD19 CAR in the forward orientation, separated by a P2A site. The restriction enzymes 
EcoRV and BamHI were then used to replace the promoter to be tested. A total of six constructs 
were generated, comparing the selected promoters RPBSA and LMP2/TAP1 with other strong 
constitutive promoters, EF1α, CMV and hPGK. LMP2/TAP1 was also cloned in the flipped 







































































































































































































3.6 Lentivirus titres using HEK293T cells 
Viral titres indicate the total number of viruses produced and were important to calculate to 
ensure the appropriate MOI was utilised for our primary T cell transduction. HEK293T cells 
were transduced with lentivirus containing each construct. After three days, transduced cells 
were analysed by flow cytometry to determine the percentage of GFP positive cells (Figure 14). 
This analysis was performed once. Viral titres for dual CAR constructs were found to be 20-30 
times lower (or two to three orders of magnitudes lower) when compared to the singular CAR 






Figure 14 Viral titre is reduced with an additional CD20 CAR cassette in the reverse orientation. 
A MOI of 20 was used to transduce HEK293T. A) Cells were left for three days before GFP 
expression was checked with flow cytometry. B) Viral titre was then calculated from percent 
positive cell number of GFP, gate percentage as stated. 
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3.7 c-Myc and Strep tags staining of transduced HEK293T cells 
c-Myc and Strep tags were incorporated into our CAR constructs to allow quantification of cell 
surface expression. With the use of specific anti-c-Myc and -Strep antibodies we were able to 
gauge the level of the CAR scFv being expressed without anti-scFv specific antibodies. CAR 
constructs were designed with the c-Myc tag expressed with the anti-CD19 CAR in the sense 
direction and Strep tag expressed with the anti-CD20 CAR in the antisense direction (Figure 
13), this should allow the presence of both CAR constructs to be detected on the same cell 
surface. This analysis was performed once. As seen in Figure 15, the anti-CD19 CAR was 
expressed on the cell surface using all promoters; however, the anti-CD20 CAR had very low 
to no expression in all promoter constructs (Figure 16). This indicated that all promoters 
investigated were not strong enough to drive a CAR construct in the reverse orientation. 
However, as activity can significantly differ between cell types, we next investigated the use of 








Figure 15 The anti-CD19 CAR is expressed on the cell surface when in the sense/forward 
orientation. A MOI of 20 was used to transduce HEK293T cells and were left for three days. 
HEK293T cells were then stained for c-Myc tag to check cell surface expression using flow 






Figure 16 The anti-CD20 CAR has low to no cell surface expression in all promoter constructs. 
A MOI of 20 was used to transduce HEK293T cells and were left for three days. HEK293T cells 
were then stained for Strep tag to check cell surface expression using flow cytometry, gate 
percentage as stated. 
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3.8 Percentage of successfully transduced primary T cells using lentivirus 
Primary T cells are essential cells involved in clearing cancerous cells from the body. As such, 
primary T cells were the final cells to be investigated in vitro to determine whether our 
constructs will be usable as a viable treatment. As in Figure 14 with HEK293T cells, we utilised 
the percentage of the population that were GFP-positive as an indication of the successful 
integration of our constructs into the genome. We utilised three different donors of PBMCs to 
determine if biological diversity would affect the expression of our different constructs. As 
shown in Figure 17, none of our constructs expressed GFP in any of the donors. The populations 
using all constructs in all donors had less than one percent expression of GFP. This indicates 
that the bidirectional approach to the bicistronic expression of dual CARs is not a viable strategy 
when combined with the lentiviral transduction delivery system. As the transduction rate was 
not efficient enough to produce a sufficient number of CAR T cells, further cell surface staining 






Figure 17 Nil GFP expression in primary T cells amongst all donors and promoters.  Activated 
primary T cells were transduced with lentivirus for each construct, respectively, and left for three 
days before analysis by flow cytometry to check for GFP expression, gate percentage as stated. 













Antigen loss is the resulting phenomenon from single antigen targeted immunotherapies against 
cancerous cells. This allows the cancer to evade treatment via the selection of mutated versions 
of the antigen that is no longer expressed or recognised by the immunotherapy (4,5). By 
targeting two antigens in the same treatment, antigen loss can be reduced (4); however, this can 
result in the doubling of costs as well as reduced transduction efficiency from large plasmid 
sizes (52). Therefore, we propose the use of a constitutive bidirectional promoter to express two 
CARs in both the sense and anti-sense directions. This has the potential to reduce antigen loss 
occurring while maintaining low production costs and high transduction rates. 
Previous work on bidirectional promoters for CAR T cell therapy has involved splicing small 
minimal constitutive promoters together in a head-to-head orientation to achieve the 
bidirectional effect (73). Huang et al. demonstrated that while splicing the minimal promoters 
for CMV and hPGK did lead to the expression of a dual CAR phenotype, problems occurred in 
vivo when the anti-tumour effects slowed, represented by the re-emergence of tumour (73). This 
is theorised to have occurred due to promoter interference (74), an occurrence that upregulates 
one promoter through the suppression of the other (75). A single bidirectional constitutive 
promoter could overcome this. Selection of a constitutive bidirectional promoter that already 
exists in the human genome would indicate persistent expression in both the sense and the 
antisense directions, overcoming the issue of promoter interference. Therefore, we set out to 
screen for small constitutive promoters in the human genome. 
We trialled and screened for strong bidirectional promoters that had the potential for CAR T 
cell therapy use. Promoters were bioinformatically screened for over-represented transcription 
factors found in bidirectional promoters. The transcription factors that were screened were  
NF-Y, YY1, GABP-α, ZNF143, NRF-1 (36). All of these important transcription factors were 
enriched in the RPBSA promoter (Figure 4). It was observed that ribosomal promoters were 
enriched for GABP-α and YY1, lending credibility to RPBSA as a bidirectional promoter (76). 
As RPBSA used a ribosomal promoter (RPL13a) as a base, this would indicate that ribosomal 
promoters are inherently bidirectional. As the LMP2/TAP1 promoter is not enriched for many 
of these transcription factors, with a singular NF-Y binding site, we theorised that LMP2/TAP1 
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would be the weakest bidirectional promoter. Interestingly, while EF1α is twice the size of the 
other two promoters and lacking in GABP-α and ZNF143/staf binding sites, EF1α was shown 
to possess bidirectional activity by Chakravarti et al. (71). 
To determine whether our bidirectional promoters were capable of expressing two CAR 
constructs, we initially utilised the fluorescent reporter proteins RFP and GFP. These proteins 
were used over other commonly used reporter genes such as luciferase, as these would have 
required additional reagents and experimentation. After validation of bidirectional activity, the 
anti-CD19 and CD20 CARs were selected due to their known strong activation to their 
respective antigens. Both of these CARs are currently in clinical trials for therapy against B cell 
lymphoma (77), while anti-CD19 CAR T cell therapy has already been approved by the FDA 
as a treatment for B-ALL (19,78). While the combination of these two CARs has been 
commonly used to determine antigen loss treatment in B-ALL by others previously, albeit, by 
other methods (5), the use of the anti-CD19 and CD20 CARs within this study is purely for 
experimental proof of concept. Should a bidirectional promoter be strong enough to sufficiently 
express a dual CAR phenotype, any combination of CARs could potentially be used to prevent 
antigen loss in other forms of cancers. 
HEK293T (Human epithelial kidney cells 293 T) cells were chosen for initial work for multiple 
reasons. The transient transfection of HEK293T cells has been used as a confirmatory tool for 
the rapid confirmation of promoter and genes of all types. HEK293T cells are ideal as they are 
suitable for expressing most mammalian proteins that require folding as well as post-
translational modification (79). The cationic lipid-DNA complex formed using the 
Lipofectamine 3000 transfection system is taken up by the HEK293T cell by endocytosis, 
allowing for efficient transfer of transgenes. Hence transfection to protein expression can occur 
in as little as three days, allowing for efficient data collection on initial findings in a human cell 
line before proceeding to more appropriate cell lines. As the transfection is only transient, 
selection media with antibiotics are not required. Similarly, due to the high transfection rate, 
recovery time is minimal before analysis (80).  
To measure the strength of our promoters, multiple methods were used to visualise and quantify 
their expression. Fluorescent microscopy was used to visualise the expression of the fluorescent 
proteins but does not provide quantification on the percentage of the population that is positive 
or the strength of the promoter. Quantitative PCR measures the number of mRNA molecules 
in a cell by amplifying a fragment specific to the target mRNA (81). The fluorescent dye  
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(SYBR green) is bound to amplified double stranded fragments before being released for further 
amplification. If the initial mRNA number is high, then a detectable level of fluorescence will 
occur at a lower cycle number and vice versa. The resulting cell cycle is normalised against a 
housekeeping gene, such as β-actin. Unfortunately a pitfall of qPCR is that it does not account 
for individual cells, only the general population trend (82). Flow cytometry was therefore 
utilised to allow for accurate quantification of the GFP and RFP levels expressed by individual 
cells. As we utilised three different validation methods, this increased our confidence in the 
experimental findings. 
WT RPBSA was the strongest promoter, as confirmed by all methods. Next, we investigated 
which regions of RPBSA were essential for activity. After the deletion of the intron in WT 
RPBSA, expression in both RFP and GFP was reduced. However, after the deletion of both the 
intron and exons, leaving only the RPL13a promoter fragment, expression was restored to WT 
RPBSA levels (Figures 6-8). This suggests that in the case of RPBSA, the activation effects are 
being negated by the exon’s inhibitory effect on the promoter function. A future RPBSA variant 
that may exhibit higher expression would be RPBSA with only the exons removed, this would 
also aid to determine the intron strength. The promoters EF1α and LMP2/TAP1 (LT) were also 
confirmed as bidirectional (Figures 6-8). EF1α was determined to be a strong bidirectional 
promoter; however, it is also twice the size of RPBSA and requires an enhancer sequence 
(57,70,71). LMP2/TAP1 was determined to be weaker than RPBSA in HEK293T cells. We 
theorised this was due to the lack of an intact IFN-γ pathway, without which would prevent the 
upregulation of genes under LMP2/TAP1 regulation, as well as the lack of other transcription 
factors found in bidirectional promoters such as RPBSA. As EF1α remained a very strong 
promoter, and the LMP2/TAP1 promoter’s potential using IFN-γ was not fully shown, both 
these promoters were carried through to determine their activity within the Jurkat cell line, 
along with the three variants of RPBSA. 
Jurkat cells were transfected and the cell line cultured for 60 days to determine the long-term 
stability and expression of our promoter constructs. Due to the nature of CAR T cell therapy, 
persistence for extended periods of time is required to clear the cancer (13). Jurkat cells were 
selected for this experiment as they are a T helper cell line, an accurate model for human T cell 
activation and activity (83). On day 30, RPBSA and its deletion variants showed a similar trend 
in Jurkat cells as HEK293T cells (Figures 9-12). The EF1α promoter continued as the strongest 
expressing promoter in both orientations. Interestingly, LMP2/TAP1 showed greater strength 
in Jurkat cells, as well as having the second highest GFP MFI (Table 5). This supports the 
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theory that HEK293T cells could not produce high expression due to a lack of an intact IFN-γ 
pathway, accounting for the difference in expression between the two cell types. At day 60, 
although similar trends were once again observed between RPBSA and its variants, both the 
MFI and percent positive numbers dropped. This could be due to the methylation of promoter 
sequences to silence the expression of unnecessary proteins (84). Methylation occurs at CpG 
sites in DNA sequences, which is enriched in bidirectional promoters (36,84). Surprisingly, WT 
RPBSA was observed to be the strongest out of the three RPBSA variants by a large margin at 
day 60 (Figures 11 and 12), indicating that the exons and introns may play a role in the 
persistence of expression, which are not observable at one week (Figures 6-8) and 30 days 
(Figures 9 and 10). Additionally, ribosomal proteins are involved in the proliferation of T cells 
and are therefore downregulated to prevent a prolonged immune response (85). WT RPBSA 
and its exons and intron may protect cells from this downregulation, while the deletion variants 
lack this protection. EF1α, which while it remained as the highest expressing promoter, also 
experienced a drop in expression in both orientations, in particular a drastic drop in the forward 
direction was observed (86). A potential explanation for this observed downregulation may be 
linked to the fact that the gene EF1α complexes with the proteins PAP1 and TXK, which in 
turn bind to the IFN-γ promoter and affect IFN-γ expression (86). Specifically, a prolonged 
IFN-γ response is unwanted in the human body as it can lead to negative side effects resulting 
in cytokine release syndrome (87). Hence a downregulation of the EF1α gene after 60 days, 
which would be considered a prolonged immune response, therefore would explain the sudden 
drop in expression from the EF1α promoter. LMP2/TAP1 promoter was also reduced at day 
60; however, its expression in both orientations was reduced the least. This was represented as 
the population with the most persistent expression after day 60, as well as possessing the highest 
percent positive population (Figures 11 and 12). LMP2/TAP1 proteins are involved with the 
antigen processing and loading onto MHC-I and hence are essential to a fully functioning 
MHC-I mediated immune response (66,88). We hypothesise that the LMP2/TAP1 promoter 
therefore cannot be silenced to the same degree that non-essential proteins of the immune 
response are e.g. ribosomal proteins and tRNAs.  
Unfortunately, while Jurkat cells are an accurate model for T cell activity, they are not CD8+ 
T cells and therefore cannot utilise cytotoxic functions. Cytotoxic activity is essential to the 
functionality of a CAR T cell (17,22). Therefore, as cytotoxicity levels cannot be assessed 
within the Jurkat cell line, a lentiviral vector vehicle was utilised to deliver our CAR T cell 
constructs to human PBMC-derived primary T cells, which include CD8+ T cells. The lentiviral 
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vector was utilised in this case as it has the highest transduction/transfection rate to date and is 
the gold standard for CAR T cell work (89). While the Sleeping Beauty transposon system has 
advantages attributed to its inherent safety, the transfection rates are not as high and 
consequently require either more time for cell recovery or multiple transfections to achieve the 
appropriate numbers for patient treatment (64,90). Despite clinical trials utilising the Sleeping 
Beauty transposon system, until rates can be increased, lentiviral vectors will continue to be 
utilised (64,90). 
In vitro investigation with primary T cells is generally the final step before moving into in vivo 
work with murine models. However, isolation and activation of primary T cells are both 
expensive to achieve. HEK293T cells were therefore initially utilised to determine whether the 
lentivirus produced using our bidirectional constructs was capable of producing high viral titres 
and integrating into the genome successfully. To quantify this, GFP was added to the construct, 
separated by a P2A site from the CD19 CAR. By calculating the percentage of cells GFP-
positive using flow cytometry, we can subsequently calculate the total functioning viral titre 
produced. Our bidirectional constructs were compared with single CAR constructs produced to 
determine the effects of adding a second CAR construct in the antisense direction. As seen in 
Figure 14, GFP expression was observed to drop dramatically when compared to their single 
CAR constructs across all promoter constructs. We hypothesise that the addition of a large 
transgene insert has interfered with either the packaging of the genome or the stoichiometry 
ratio between the genome and capsid which could affect the ability for the RNA genome to be 
packaged into the capsid as described by Kumar et al. (91). Alternatively, the integration step 
may have been impacted by the resulting large DNA construct, reducing the integrase’s ability 
to insert the transgenes into the host genome (92). 
As GFP was only an indicator for successful transduction, flow cytometric staining for the tags 
c-Myc and Strep were also performed (Figures 15 and 16). c-Myc and Strep are known reporter 
tags commonly utilised to detect fusion proteins and are often used in CAR cell surface 
detection (93–95). The c-Myc tag comes from the transcription factor c-Myc (96), while the 
Strep tag was isolated using a random genetic library to find a peptide sequence specific for 
core streptavidin (97). The presence of these tags allows for simple CAR detection without the 
need for different detection protocols for each different CAR. However, as we were detecting 
the presence of two different CARs on the same cell surface, different tags were required to 
acquire accurate measurements. As shown in Figure 15, despite staining of more than 20% on 
untransduced cells, the single CD19 CAR showed very high levels of c-Myc staining. 
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Comparatively, upon the addition of our second CAR construct, c-Myc staining was reduced, 
indicating an inhibition of expression. Similarly, there is little to no detectable strep tag on the 
cell surface when compared with the single CD20 CAR construct. From past studies, we know 
that the CMV (98) and hPGK (99) promoters show either no or very little bidirectional activity, 
respectively, therefore detection of the strep tag was not expected. However, as shown in 
Figures 6-8, EF1α, RPBSA, and LMP2/TAP1 promoters have all shown bidirectional activity 
in HEK293T. This result indicates that they either are simply are not strong enough to drive the 
expression of both the GFP-P2A-CAR19 transcript and the CAR20 transcript, or the lentiviral 
delivery system was not efficient enough to integrate a construct of this size (52). Interestingly, 
the LMP2/TAP1 promoter showed the highest expression of the reverse transcript. We 
hypothesise that this was due to LMP2/TAP1 being the only bidirectional promoter in its 
naturally occurring form (66,88). 
While the expression of both CARs was very low compared with their single CAR counterparts, 
promoter activity can vary greatly between cell types. Therefore, we next transduced purified 
and activated primary T cells to determine whether our selected promoters were strong enough 
to express our constructs in a primary T cell setting. To account for biological diversity amongst 
individuals, PBMC from three different donors were utilised to validate any results that were 
collected. Initially, GFP activity was once again quantified using flow cytometry to determine 
the percent of the population that was successfully transduced. According to Figure 17, the 
level of transduction was incredibly low amongst all donors and promoter constructs when 
compared to the single CAR controls. The level of transduction was not viable for further 
experimentation or possible development into a treatment. Taken together with the results 
collected from the HEK293T experiments (Figures 14-16), we can conclude that when using 
the lentiviral system, the addition of a second CAR construct results in a 30-fold reduction in 
the total number of viable lentivirus. Even when an appropriate number of viruses is utilised to 
transduce HEK293T cells, the promoters tested were not strong enough to express the CARs. 
4.2 Future directions 
While these promoters were validated as both bidirectional and capable of persisting for up to 
60 days, the capability to express two CARs in a single construct was not achieved. This may 
have been due to the lentiviral delivery system losing efficiency when packaging and 
integrating large constructs (52). Therefore, the next step would be testing whether the Sleeping 
Beauty transposon system is more effective in delivering our constructs to primary T cells.  
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A further possibility is that our promoters were simply not strong enough to run large transcripts 
in both the sense and antisense directions (Figure 14). To further assess this we would place 
both CARs under the control of a single promoter, as this has been demonstrated to work 
successfully by Ruella et al. and Wang et al. using CD19 and CD137, and IL-23 and PSMA, 
respectively (32,100). As primary T cells consist of CD8+ cytotoxic T cells, a cytotoxic killing 
assay would then be performed, utilising transiently transfected HEK293T cells with GFP as 
well as either CD19 antigen and/or CD20 antigen as target cells. If our promoters are strong 
enough to express both CAR constructs at the same time, there should be cell death in both the 
singular and dual antigen expressing cells. The cytotoxic killing assay would then be analysed 
by two different methods: flow cytometry and an ELISA. The use of flow cytometry would 
allow us to measure the number of dead cells by live-dead cell staining, as well as GFP 
expression. This would allow us to determine whether our dual expressing CAR T cells are 
capable of killing cancerous cells. An ELISA testing for the concentration of IL-2, a cytokine 
released during activation and proliferation of T cells, would allow us to determine whether the 
CAR T cells are activated. Should these strategies be successful, a combination of different 
CAR constructs could be utilised to meet the requirements of other cancerous environments or 
genetic circuits. For example, a dual inhibitory CAR (iCAR)/CAR genetic circuit can be 
designed to improve the safety of the treatment. The iCAR would target an antigen found on 
healthy cells, inducing apoptosis in CAR T cells should they come in contact with healthy cells. 
The other CAR would target a cancerous antigen, thus allowing the CAR to activate only in the 
presence of cancerous tissue and nowhere else. Other strategies include splitting the activation 
domains of a CAR between two CARs so activation can occur only in the presence of two 
cancerous antigens to improve specificity and prevent off target effects, as well as the use of 
both CD28 and 4-1BB domains between two constructs for the benefits of both domains.  
Following successful in vitro studies, the next step would be to move into in vivo murine 
studies. NOD-scid IL2Rγnull (NSG) mice would be utilised for these studies, as they are lacking 
a functional immune system. This allows us to place a human tumour within and transfuse the 
mice with human CAR T cells without risk of spontaneous rejection, hence granting us the 
ability to test their functionality in an accurate in vivo model. 
For bidirectional promoter work, other viable genetic circuits could be developed. While not 
strong enough to run a large gene such as a CAR, they may be strong enough to express a 
smaller gene. We would test a variety of genes that aid in either lentiviral packaging or the 
treatment of the cancer. Another example of potential bidirectional promoter utility is antibody 
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expression, as the heavy and light chains and their respective constant regions are only 700 base 
pairs each. EF1α, RPBSA, and LMP2/TAP1 have all been shown to possess the capability to 
express transcripts of this size as shown in this thesis (Figures 6-12). 
4.3 Conclusion 
In conclusion, a reporter vector using the Sleeping Beauty transposon system was developed to 
determine the bidirectional activity for promoters using RFP and GFP. The promoters EF1α, 
RPBSA, its deletion variants RPBSA ∆Intron and RPBSA ∆Intron and exons 1+2, and 
LMP2/TAP1 all showed bidirectional activity in HEK293T cells and maintained activity over 
60 days in Jurkat cells. The activity was reduced in RPBSA when the intron was deleted; 
however, activity was increased upon further deletion of the exons. Interestingly, at 60 days the 
WT RPBSA showed the least reduction in bidirectional activity when compared to its deletion 
variants and was used for further experimentation. When these promoters were compared with 
other constitutive promoters to determine their ability to express a dual CAR phenotype, the 
expression of the CAR in the sense orientation was reduced while the CAR in the antisense 
direction was barely expressed in HEK293T cells. When applying our construct into a lentiviral 
vector, the viral titre and transduction rate were shown to be very low compared with the single 
CAR controls. These findings show that lentiviral transduction is not capable of producing 
viable viruses in large numbers and that the promoters are not capable of expressing two CAR 
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